免疫細胞激素市場規模、佔有率和成長分析：按類型、細胞激素類型、治療應用、目標抗原、最終用戶和地區分類－2026-2033年產業預測

2024 年全球免疫細胞激素市場價值為 38.2 億美元，預計到 2025 年將成長至 42.6 億美元，到 2033 年將成長至 101.8 億美元，在預測期（2026-2033 年）內複合年成長率為 11.5%。

全球免疫細胞激素市場主要由生物製藥將細胞激素與腫瘤靶向抗體偶聯，以最佳化免疫反應並保護健康組織。這種融合將腫瘤的「冷」微環境轉化為發炎狀態，使其能夠有效回應查核點抑制劑。蛋白質工程技術的進步顯著推動了市場成長，IL-2 與抗 GD2 抗體的成功結合便是一個典型例證。這增強了投資者的信心，並拓展了針對血液腫瘤和固體癌的研發管線。一個值得關注的趨勢是，市場對將細胞激素遞送與查核點療法和細胞療法融合的聯合治療的需求日益成長，以增強治療效果。此外，人工智慧技術在加速標靶識別、最佳化融合設計以及簡化臨床前試驗方面發揮著至關重要的作用，從而促進了該領域的創新與合作。

全球免疫細胞激素市場成長要素

全球免疫細胞激素市場的主要驅動力是與細胞激素結合的高特異性抗體片段的開發。這項創新實現了標靶腫瘤治療，在病灶部位直接激活免疫系統，同時最大限度地減少脫靶效應。這些進展增強了臨床醫生和患者的信心，並提高了免疫細胞激素療法作為個人化治療方案關鍵組成部分的接受度。因此，這種信心的增強刺激了研發投入，促進了生物技術公司與學術機構之間的合作，並推動了滿足未被滿足的醫療需求的新藥的上市，最終創造了一個充滿活力的環境，進一步加速了市場成長。

全球免疫細胞激素市場的限制因素

全球免疫細胞激素市場面臨許多阻礙其成長的重大挑戰。將細胞激素組分精確結合到單株抗體骨架上需要專門的生物製程設施、嚴格的無菌條件和全面的分析特性。這些技術要求推高了營運成本並延長了研發週期，使得中小企業難以進入市場。因此，製造商傾向於將資源集中於更大規模的生物製藥產品，從而限制了整體市場的發展勢頭。此外，低溫運輸物流和全面的穩定性測試要求也使供應鏈管理更加複雜，進一步阻礙了其廣泛應用，尤其是在基礎設施不足的新興市場。

全球免疫細胞激素市場趨勢

全球免疫細胞激素市場正經歷著向個人化癌症治療的顯著轉變，臨床醫生優先考慮針對腫瘤獨特分子特徵量身定做的免疫細胞激素。這種對定製製劑的偏好源於對更高療效和更低脫靶毒性的預期。因此，製藥公司正在增加對先進平台技術的投資，以支援高效的抗體-細胞激素組合和高度適應性的連接子設計。隨著腫瘤學家採用精準醫療方法，患者選擇方法也在不斷發展，學術機構和生技公司之間正在建立合作網路。這些合作旨在共同開發個人化治療方案，最終使全球不同患者群體都能獲得有效的治療。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球免疫細胞激素市場規模：按類型分類

• 基於單株抗體的免疫細胞激素
• 基於抗體片段的免疫細胞激素
• 基於融合蛋白的免疫細胞激素

全球免疫細胞激素市場規模：以細胞激素類型分類

• 白細胞介素（IL）系統
• 干擾素（IFN）
• 腫瘤壞死因子（TNF）系統
• 其他細胞激素系統（免疫細胞激素）

全球免疫細胞激素市場規模：依治療應用分類

• 固體癌
• 骨髓惡性腫瘤
• 自體免疫疾病
• 感染疾病
• 其他

全球免疫細胞激素市場規模：以標靶抗原分類

• 腫瘤相關抗原（TAA）
• 免疫細胞表面標誌物
• 腫瘤微環境的標靶
• 其他

全球免疫細胞激素市場規模：依最終用戶分類

• 醫院
• 專科癌症中心
• 研究和學術機構
• 生物技術和製藥公司

全球免疫細胞激素市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Xencor Inc
• Philogen S p A
• Cytimmune Sciences Inc
• Cytune Pharma SAS
• SunHo BioPharmaceutical Co Ltd
• Merck & Co Inc
• Merck KGaA
• F Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• AstraZeneca plc
• Bristol Myers Squibb Company
• Amgen Inc
• Novartis AG
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Sari Therapeutics
• Nektar Therapeutics
• Anavex Life Sciences Corp
• ImmunoGen Inc

結論與建議

Global Immunocytokines Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 4.26 Billion in 2025 to USD 10.18 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The global immunocytokines market is driven by biologic agents that connect cytokines to tumor-targeting antibodies, optimizing immune responses while protecting healthy tissue. This fusion transforms cold tumor microenvironments into inflamed states that can effectively respond to checkpoint inhibition. Advances in protein engineering have significantly influenced market growth, as evidenced by successful combinations of IL-2 with anti-GD2 antibodies, fostering investor confidence and expanding pipeline options to include both hematologic and solid tumors. A notable trend is the increasing demand for combination therapies that merge cytokine delivery with checkpoint or cell therapies, enhancing therapeutic efficacy. Moreover, AI technology plays a crucial role by expediting target identification, optimizing fusion designs, and streamlining pre-clinical testing, thus encouraging innovation and collaboration within the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunocytokines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunocytokines Market Segments Analysis

Global immunocytokines market is segmented by type, cytokine type, therapeutic application, target antigen, end user and region. Based on type, the market is segmented into Monoclonal Antibody-Based Immunocytokines, Antibody Fragment-Based Immunocytokines and Fusion Protein-Based Immunocytokines. Based on cytokine type, the market is segmented into Interleukin (IL)-Based, Interferon (IFN)-Based, Tumor Necrosis Factor (TNF)-Based and Other Cytokine-Based Immunocytokines. Based on therapeutic application, the market is segmented into Solid Tumors, Hematological Malignancies, Autoimmune Diseases, Infectious Diseases and Others. Based on target antigen, the market is segmented into Tumor-Associated Antigens (TAAs), Immune Cell Surface Markers, Tumor Microenvironment Targets and Others. Based on end user, the market is segmented into Hospitals, Specialty Cancer Centers, Research & Academic Institutes and Biotechnology & Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immunocytokines Market

The global immunocytokines market is significantly driven by the development of highly specific antibody fragments that are conjugated with cytokines. This innovation allows for targeted tumor treatment, minimizing off-target effects while promoting immune activation directly at disease sites. Such advancements instill confidence in both clinicians and patients, leading to an increased acceptance of immunocytokine therapies as vital components of personalized treatment approaches. Consequently, this rise in confidence stimulates investment in research and development, fosters collaborations between biotechnology firms and academic institutions, and supports the introduction of new candidates to meet unmet clinical needs, thereby creating a dynamic environment that further propels market growth.

Restraints in the Global Immunocytokines Market

The Global Immunocytokines market faces several significant challenges that hinder its growth. The precise conjugation of cytokine components to monoclonal antibody frameworks necessitates specialized bioprocessing facilities, strict aseptic conditions, and thorough analytical characterization. These technical requirements elevate operational costs and prolong development timelines, making it difficult for smaller companies to penetrate the market. As a result, manufacturers are inclined to focus their resources on more scalable biologics, which limits overall market momentum. Furthermore, the necessity for cold-chain logistics and comprehensive stability testing complicates supply chain management, posing additional obstacles to widespread adoption, particularly in emerging markets with inadequate infrastructure.

Market Trends of the Global Immunocytokines Market

The Global Immunocytokines market is witnessing a compelling trend towards personalized oncology, as clinicians prioritize immunocytokines tailored to the unique molecular profiles of tumors. This preference for bespoke constructs arises from the potential for enhanced efficacy and minimized off-target toxicity. Consequently, pharmaceutical companies are increasing investments in advanced platform technologies that support efficient antibody-cytokine pairing and adaptable linker design. As oncologists adopt precision medicine approaches, patient selection methods are evolving, leading to the establishment of collaborative networks between academic institutions and biotech firms. This collaboration aims to co-develop customized treatment regimens, ultimately expanding access to effective therapies for diverse patient populations worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Immunocytokines Market Size by Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibody-Based Immunocytokines
• Antibody Fragment-Based Immunocytokines
• Fusion Protein-Based Immunocytokines

Global Immunocytokines Market Size by Cytokine Type & CAGR (2026-2033)

• Market Overview
• Interleukin (IL)-Based
• Interferon (IFN)-Based
• Tumor Necrosis Factor (TNF)-Based
• Other Cytokine-Based Immunocytokines

Global Immunocytokines Market Size by Therapeutic Application & CAGR (2026-2033)

• Market Overview
• Solid Tumors
• Hematological Malignancies
• Autoimmune Diseases
• Infectious Diseases
• Others

Global Immunocytokines Market Size by Target Antigen & CAGR (2026-2033)

• Market Overview
• Tumor-Associated Antigens (TAAs)
• Immune Cell Surface Markers
• Tumor Microenvironment Targets
• Others

Global Immunocytokines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Cancer Centers
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies

Global Immunocytokines Market Size & CAGR (2026-2033)

• North America (Type, Cytokine Type, Therapeutic Application, Target Antigen, End User)
  • US
  • Canada
• Europe (Type, Cytokine Type, Therapeutic Application, Target Antigen, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Cytokine Type, Therapeutic Application, Target Antigen, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Cytokine Type, Therapeutic Application, Target Antigen, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Cytokine Type, Therapeutic Application, Target Antigen, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Xencor Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philogen S p A
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytimmune Sciences Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytune Pharma S A S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SunHo BioPharmaceutical Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sari Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nektar Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoGen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations